Sequence-Based Human Leukocyte Antigen—B Typing of Patients Infected with Ebola Virus in Uganda in 2000: Identification of Alleles Associated with Fatal and Nonfatal Disease Outcomes

Sequence-Based Human Leukocyte Antigen—B Typing of Patients Infected with Ebola Virus in Uganda in 2000: Identification of Alleles Associated with Fatal and Nonfatal Disease Outcomes

1. Anthony Sanchez, 
2. Kent E. Wagonera and 
3. Pierre E. Rollin

+Author Affiliations

1. Special Pathogens Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia

+Author Notes

• ↵a Present affiliation: Center for Health Sciences, Ithaca College, Ithaca, New York.

1. Reprints or correspondence: Dr. Anthony Sanchez, Special Pathogens Branch, Div. of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Mailstop G-14, Atlanta, Georgia 30333 (ans1@cdc.gov).

Abstract

The Sudan species of Ebola virus (SEBOV) causes severe, often fatal infection in ∼50% of infected humans. We sought to determine whether the human leukocyte antigen—B (HLA-B) locus has a role in the outcome of SEBOV disease by typing 77 cases from an outbreak in northern Uganda in 2000–2001. Sequence-based HLA-B typing was performed using leukocytes isolated from 77 patients. Statistical analysis and a predictive discriminant analysis (PDA) were applied to typing data. Epitope prediction software was also applied to SEBOV sequences. Statistically significant associations were found between certain sets of alleles and either fatal or nonfatal disease outcomes. Alleles B*67 and B*15 were associated with fatal outcomes, whereas B*07 and B*14 were associated with nonfatal outcomes. The PDA-derived functions that were produced were 81.8% accurate in classifying patients into their correct outcome group. Several epitopes predicted to bind strongly to HLA-B*07 molecules were identified in the viral polymerase, nucleoprotein, and VP35 protein. HLA-B alleles associated with either fatal or nonfatal outcomes of SEBOV disease were identified and can be used in a predictive model. Studies of HLA-B—restricted epitopes could contribute to characterization of protective host responses and to vaccine development.

Articles citing this article

• Ebola Hemorrhagic Fever: Novel Biomarker Correlates of Clinical OutcomeThe Journal of Infectious Disease (2014) 210 (4): 558-566
  • Abstract
  • Full Text (HTML)
  • Full Text (PDF)
• Structural basis for Marburg virus VP35-mediated immune evasion mechanismsProc. Natl. Acad. Sci. USA (2012) 109 (50): 20661-20666
  • Abstract
  • Full Text (HTML)
  • Full Text (PDF)
• Real-time Monitoring of Cardiovascular Function in Rhesus Macaques Infected With Zaire ebolavirusThe Journal of Infectious Disease (2011) 204 (suppl_3): S1000-S1010
  • Abstract
  • Full Text (HTML)
  • Full Text (PDF)
• Research Ethics and International Epidemic Response: The Case of Ebola and Marburg Hemorrhagic FeversPublic Health Ethics (2009) 2 (1): 7-29
  • Abstract
  • Full Text (HTML)
  • Full Text (PDF)
• Filovirus Research: Knowledge Expands to Meet a Growing ThreatThe Journal of Infectious Disease (2007) 196 (Supplement_2): S438-S443
  • Full Text (HTML)
  • Full Text (PDF)
• Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic FeverThe Journal of Infectious Disease (2007) 196 (Supplement_2): S390-S399
  • Abstract
  • Full Text (HTML)
  • Full Text (PDF)